RECOMBUMIN
LIVE

Serial Number

79345867

Owner

Albumedix Ltd

Attorney

Karen Lim

Filing Date

May 26, 2022

Add to watchlist:

No watchlists yet
View on USPTO

RECOMBUMIN Trademark

Serial Number: 79345867 • Registration: 7362015

RECOMBUMIN is a trademark filed by Albumedix Ltd on May 26, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Albumedix Ltd (16 trademarks)

HQ, Mabel Street

Entity Type: 99

Sartorius Albumedix Limited (8 trademarks)

HQ, Mabel Street

Entity Type: 98

Trademark Details

Filing Date

May 26, 2022

Registration Date

April 23, 2024

Published for Opposition

February 6, 2024

Goods & Services

Pharmaceuticals for the treatment or prophylaxis of viral, bacterial, fungal, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological, neurodegenerative, neuromuscular, central nervous system, gastrointestinal, hormonal, dermatological, psychiatric, immune system, urinary, angiogenic, genetic, menopausal, and pain related diseases and disorders; pharmaceutical products and substances for the treatment or prophylaxis of viral, bacterial, fungal, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological, neurodegenerative, neuromuscular, central nervous system, gastrointestinal, hormonal, dermatological, psychiatric, immune system, urinary, angiogenic, genetic, menopausal, and pain related diseases and disorders; albumin, chemical preparations, synthetic peptides, protein supplements, monoclonal, polyclonal, immunological, native and recombinant antibodies for medical and veterinary use, cells for medical and veterinary use, viruses, live viruses, live- attenuated viruses, attenuated viruses, and virus-like particles and viral vectors for medical and veterinary use, vaccines, growth factors for medical and veterinary use, immune modulators for medical and veterinary use, monoclonal antibodies, biological tissue and tissue cultures, recombinant proteins for medical and veterinary use, nucleic acid sequences, blood plasma, blood components for medical and veterinary use, all being for pharmaceutical use for the treatment or prophylaxis of viral, bacterial, fungal, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological, neurodegenerative, neuromuscular, central nervous system, gastrointestinal, hormonal, dermatological, psychiatric, immune system, urinary, angiogenic, genetic, menopausal, and pain related diseases and disorders; reagents for medical use; diagnostic reagents for medical use; protein supplements for pharmaceutical purposes; albuminous preparations for medical or veterinary purposes; recombinant albumin for biological therapeutic purposes

Chemicals used in industry, science and for use in the manufacture of pharmaceuticals; chemical reagents other than for medical or veterinary purposes; diagnostic reagents and preparations, other than for medical or veterinary purposes; chemical excipients for use in the manufacture of pharmaceutical preparations; proteins for industrial purposes; recombinant human albumin for use as a stabilizer and excipient for industrial purposes and for use in the manufacture of cell culture media, cell and tissue storage and preservation media and for the manufacture of diagnostic imaging agents; cell culture reagents for scientific and research use, and chemical preservation reagents for scientific and research use; albumin for use in the manufacture of pharmaceutical products, vaccines, cellular therapies, regenerative medicines and gene therapies; protein in raw material form for scientific and medical research

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 16, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 16, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 16, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 16, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 16, 2025 COAR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Apr 11, 2025 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 9, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 23, 2024 FICS
FINAL DISPOSITION PROCESSED
Oct 23, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 24, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 23, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 23, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 6, 2024 NPUB
PUBLISHED FOR OPPOSITION
Feb 6, 2024 PUBO
NOTIFICATION PROCESSED BY IB
Feb 5, 2024 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 17, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 17, 2024 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 17, 2024 NONP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 13, 2024 OPNX
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 31, 2023 CNSA
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 27, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 27, 2023 OPNR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 3, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 3, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 3, 2023 TROA
REFUSAL PROCESSED BY IB
May 23, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 3, 2023 RFCS
REFUSAL PROCESSED BY MPU
May 3, 2023 RFRR
NEW REPRESENTATIVE AT IB RECEIVED
Apr 2, 2023 NREP
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 16, 2023 RFCR
NON-FINAL ACTION WRITTEN
Mar 15, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 7, 2023 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Jan 29, 2023 NREP
APPLICATION FILING RECEIPT MAILED
Aug 2, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 29, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 27, 2022 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Jul 21, 2022 SDRC